ThromboGenics strengthens leadership team

Belgian biotech firm ThromboGenics (Euronext Brussels: THR), which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis.

ThromboGenics has appointed Susan Schneider as chief medical officer, and Vinciane Vangeersdaele as chief commercial officer. Both will be members of the company’s executive team reporting to ThromboGenics’ chief executive Patrik De Haes, and they will operate from the company’s offices in Leuven, Belgium and Iselin, New Jersey, USA.

Dr Schneider brings nearly 15 years of experience in clinical drug development to ThromboGenics. Prior to joining ThromboGenics, she was, most recently, vice president and therapeutic area head of Retina & Glaucoma at Allergan. At ThromboGenics, Dr Schneider will be responsible for the development and execution of the company’s global clinical and medical programs that are focused on its industry-leading pipeline of drug candidates targeting diabetic eye disease.